Status: Recruiting
Sacituzumab Govitecan In TNBC
This research study is studying to evaluate sacituzumab govitecan for individuals with localized triple negative breast cancer (TNBC) The names of the study drugs involved in this study is: * Sacituzumab govitecan (SG) * Pembrolizumab (combination therapy with SG)
Participants needed: 239
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Massachusetts General HospitalUpdated: Jul 17, 2026Locations: 5
Eligibility criteria
Female or male patients ≥ 18 years of age. [+16]
Participants currently receiving systemic therapy for any malignancy or having r... [+7]